Companies: 10,795·Total market cap: $144.5T
FibroGen, Inc.

FibroGen, Inc.

FGENNASDAQHealthcare
$9.07
$-0.15(-1.63%)
Market Cap$36692186
P/E Ratio
52W High$21.95
52W Low$4.85
Overview

FibroGen, Inc. (FGEN) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000921299 · FGEN · NASDAQ · as of Jun 9, 2026

Filing snapshot

1,000+
Total Filings
4/A
Latest Form
2026-05-19
Most Recent
2014
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0000921299 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-16
Fiscal Year End
Mar 16, 2026
Accession No.
0001193125-26-108346
Primary Document
kynb-20251231.htm
Source: data.sec.gov · CIK 0000921299 · Accession 0001193125-26-108346

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-12
8-KCurrent Report
8-K
2026-05-11Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-12
View
8-KCurrent Report
8-K
2026-05-11
View
ARSARS
ARS
2026-04-27
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-27
View
DEF 14AProxy Statement
DEF 14A
2026-04-27
View
8-KCurrent Report
8-K
2026-04-09
View
10-KAnnual Report
10-K
2026-03-16
View
8-KCurrent Report
8-K
2026-03-16
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
8-KCurrent Report
8-K
2026-01-07
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-11-14
View
10-QQuarterly Report
10-Q
2025-11-10
View
8-KCurrent Report
8-K
2025-11-10
View
8-KCurrent Report
8-K
2025-11-06
View
Showing 1–15 of 365 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000921299  |  Exchange: NASDAQ · Healthcare

FibroGen, Inc. (NASDAQ: FGEN) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0000921299, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is FibroGen, Inc.'s most comprehensive regulatory disclosure. The most recent FibroGen, Inc. 10-K was filed on 2026-03-16 for fiscal year ending 2026. Historical FGEN 10-K annual reports are available from 2015 through 2026.

Investors researching FibroGen, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

FGEN SEC Filings · 8 questions

FibroGen, Inc. (FGEN) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. FibroGen, Inc.'s CIK is 0000921299.

FGEN SEC filingsFibroGen, Inc. SEC documentsfind FGEN 10-K